Latest Articlesddd

A Press Release About Regeneron Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths

August 13, 2019 0

Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in …

The Value of the Biotech Companies

August 12, 2019 0

Prohost Letter #434 Special Issue The Value of the Biotech Companies With a strong economy and …

Why Amgen’s Stock Is Up Over $11 Today

August 9, 2019 0

Amgen’s Stock Is Up Amgen (AMGN) is speeding towards reaching its true, fair value. In the Q2 …

Court Upholds Validity of Amgen’s Claims Regarding Enbrel

August 9, 2019 0

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed …

Nektar’s Story Has Nothing to Do with the Efficacy Or the Value of NKTR-214

August 9, 2019 2

Nektar Therapeutics Story Everything was going well with Nektar Therapeutics (NKTR) stock during the Conference call …

Nektar Therapeutics Q2 Results for 2019 Press Release

August 9, 2019 0

Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial …

Unveiled Good News About Prohost Picked Biotech Stocks

August 8, 2019 0

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on …

Rhythm Pharmaceuticals Has Good News. See Also: The Novartis News Story

August 7, 2019 0

Rhythm Pharmaceuticals From Rhythm Pharmaceuticals (RYTM) we learned that positive, top-line results from two pivotal Phase 3 …

What We Learned from Yesterday’s and Today’s Stocks’ Moves

August 6, 2019 0

What Have We Learned from the Market's Recent Stock Moves? Well. Did we learn anything from …

Impacting News

August 6, 2019 0

In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. …

An Important Statement to Prohost Readers

August 5, 2019 0

Prohost has just finished a very hard task; evaluating its best picks from the biotechnology and …

The Nektar Good News Cannot be Hidden Any Longer

August 1, 2019 0

Nektar Therapeutics We believe that Nektar Therapeutics (NKTR) is undervalued. We base this on the firm’s technological capability. …

RegenxBio Has Good News

August 1, 2019 2

RegenxBio License Agreement with Pfizer RegenxBio (RGNX) announced a license agreement with Pfizer (PFE). Under the terms of …

Why We Decided Not To Abandon the Amgen and Illumina Band Wagons

July 30, 2019 0

Amgen Contrary to our expectations Amgen’s (AMGN) shares declined more than 10% in 2019, instead of rallying. …

Gilead Sciences Activities Are Exceeding Its All Time High. Celgene Demonstrates How Valuable It Could be for Bristol-Myers Squibb.

July 22, 2019 0

Gilead Sciences Activities There is no doubt that Gilead Sciences (GILD) is doing whatever it takes to expand, …

Halozyme and argenx Most Recent News

July 19, 2019 0

Halozyme and argenx Collaboration argenx (ARGX) dosed the first subject in phase 1 clinical trial for the …

Seattle Genetics Deserves Its Stock Rally

July 17, 2019 0

Seattle Genetics Stock Rallied Seattle Genetics (SGEN) financial results started with Clay Siegall, Ph.D., President and …

Takeda: Advancing the Potential for Off-the-Shelf, Highly Scalable and Lower Cost CAR T-Cell Therapy for Cancer Treatment.

July 17, 2019 0

CiRA, Takeda & T-CiRA Less than five years ago the Center for iPS Cell Research and Application …

The Gilead and Galapagos Agreement Is a Big Win for Both Firms and Their Shareholders

July 15, 2019 0

Gilead and Galapagos Global Research Collaboration Gilead Sciences (GILD) and Galapagos NV (GLPG) entered into a 10-year global …

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

July 15, 2019 0

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis (EXEL) we …